Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

40 hours with a standard deviation of .37 hours. "Early recognition of patients with cardiogenic shock allows for prompt treatment initiation," the study authors wrote. "Timely intervention can ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

The hospital system's shock consortium developed an algorithm to assess and treat patients with cardiogenic shock. Using the acronym SALUDE, the algorithm guides nurses and other clinicians in ...

Educating the nursing team was one of the primary elements of the initiative. The hospital system’s shock consortium developed an algorithm to assess and treat patients with cardiogenic shock. Using ...

KL4 Surfactant is under clinical development by Windtree Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

“We are pleased that istaroxime is receiving positive attention based on the recent clinical trial results in treating patients with early cardiogenic shock. We believe that pharmacologic ...

Istaroxime has been studied in four positive Phase 2 trials enrolling patients with acute heart failure and early cardiogenic shock due to heart failure. "We are pleased that istaroxime is receiving ...

Pham Van Quang, head of the Intensive Care and Anti-Poisoning Department, determined that the girl was suffering from ...

also addressing cardiogenic shock under similar clinical conditions. J&J MedTech R&D, ECP and Pediatrics Platform, Heart Recovery senior director Sonya Bhavsar said: “The opportunity to treat ...